Century Therapeutics Stock Price, News & Analysis (NASDAQ:IPSC) $1.71 +0.13 (+8.23%) (As of 10:01 AM ET) Add Compare Share Share Today's Range$1.60▼$1.7550-Day Range$1.28▼$2.0252-Week Range$1.28▼$9.71Volume302,626 shsAverage Volume136,682 shsMarket Capitalization$102.32 millionP/E RatioN/ADividend YieldN/APrice Target$13.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside748.2% Upside$13.57 Price TargetShort InterestHealthy3.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.75Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.08) to ($2.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector349th out of 948 stocksBiological Products, Except Diagnostic Industry52nd out of 147 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.57, Century Therapeutics has a forecasted upside of 748.2% from its current price of $1.60.Amount of Analyst CoverageCentury Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.06% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Century Therapeutics has recently decreased by 11.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 3.2 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Century Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.28% of the stock of Century Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to grow in the coming year, from ($2.08) to ($2.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesDecember 6, 2023 | markets.businessinsider.comCentury Therapeutics Announces IND Application Clearance For CNTY-101December 6, 2023 | msn.comCentury Therapeutics stock gains after IND clearance for lupus candidateDecember 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 6, 2023 | finance.yahoo.comCentury Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusDecember 6, 2023 | finance.yahoo.comCentury Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus ErythematosusDecember 4, 2023 | americanbankingnews.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decline in Short InterestNovember 21, 2023 | finance.yahoo.comCentury Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 15, 2023 | markets.businessinsider.comPromising Future for Century Therapeutics: Analyzing Daina Graybosch’s Buy Rating Amid Key Clinical Trials and Corporate DevelopmentsDecember 6, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | finance.yahoo.comFMR LLC Adjusts Position in Century Therapeutics IncNovember 12, 2023 | markets.businessinsider.comCentury Therapeutics: Strengthened Leadership, Solid Financials and Promising Clinical Trials Drive Buy RecommendationNovember 10, 2023 | markets.businessinsider.comWilliam Blair Reaffirms Their Hold Rating on Century Therapeutics (IPSC)November 9, 2023 | benzinga.comRecap: Century Therapeutics Q3 EarningsNovember 9, 2023 | finance.yahoo.comCentury Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory DiseasesNovember 9, 2023 | finance.yahoo.comCentury Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNovember 9, 2023 | finance.yahoo.comCentury Therapeutics Inc (IPSC) Reports Q3 2023 Financial ResultsNovember 7, 2023 | markets.businessinsider.comCentury Therapeutics’ Stock Buy Rating: Anchored on Promising Clinical Data, Solid Financials, and Innovative AlloEvasion TechnologyNovember 2, 2023 | finance.yahoo.comCentury Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and ExpositionOctober 21, 2023 | finance.yahoo.comCan Century Therapeutics (NASDAQ:IPSC) Afford To Invest In Growth?September 26, 2023 | finance.yahoo.comCentury Therapeutics to Present at the Chardan 7th Annual Genetic Medicines ConferenceSeptember 10, 2023 | thestreet.comCentury Therapeutics Inc.August 29, 2023 | msn.comJP Morgan Downgrades Century Therapeutics (IPSC)August 28, 2023 | msn.comJP Morgan cuts Century Therapeutics to neutral, cites lengthy data timelineAugust 11, 2023 | msn.comPiper Sandler Maintains Century Therapeutics (IPSC) Overweight RecommendationAugust 11, 2023 | msn.comEF Hutton Reiterates Century Therapeutics (IPSC) Buy RecommendationAugust 10, 2023 | msn.comChardan Capital Maintains Century Therapeutics (IPSC) Buy RecommendationAugust 10, 2023 | msn.comHC Wainwright & Co. Maintains Century Therapeutics (IPSC) Buy RecommendationSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$13.57 High Stock Price Target$20.00 Low Stock Price Target$5.00 Potential Upside/Downside+759.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,930,000.00 Net Margins-5,183.16% Pretax Margin-5,071.34% Return on Equity-49.28% Return on Assets-29.35% Debt Debt-to-Equity RatioN/A Current Ratio8.50 Quick Ratio8.50 Sales & Book Value Annual Sales$2.49 million Price / Sales38.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.13 per share Price / Book0.31Miscellaneous Outstanding Shares59,835,000Free Float55,288,000Market Cap$94.54 million OptionableNot Optionable Beta0.67 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Michael C. Diem M.D. (Age 52)Chief Financial Officer Comp: $650.66kDr. Adrienne Farid Ph.D. (Age 61)COO & Head of Early Development Comp: $650.66kDr. Gregory Russotti Ph.D. (Age 56)Interim President & CEO Mr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 65)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringMr. Douglas Carr CPASenior VP of Finance & Operations and SecretaryMore ExecutivesKey CompetitorsGenenta ScienceNASDAQ:GNTAMiromatrix MedicalNASDAQ:MIROOcugenNASDAQ:OCGNVaxxinityNASDAQ:VAXXAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 11,942 shares on 11/17/2023Ownership: 0.286%Avidity Partners Management LPSold 12,400 shares on 11/14/2023Ownership: 1.836%Tower Research Capital LLC TRC Bought 24,879 shares on 11/14/2023Ownership: 0.047%FMR LLCSold 643,866 shares on 11/13/2023Ownership: 7.562%Charles Schwab Investment Management Inc.Sold 13,257 shares on 11/8/2023Ownership: 0.246%View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price target for 2024? 6 analysts have issued 12-month price targets for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $20.00. On average, they expect the company's stock price to reach $13.57 in the next twelve months. This suggests a possible upside of 759.0% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2023? Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC shares have decreased by 69.2% and is now trading at $1.58. View the best growth stocks for 2023 here. Are investors shorting Century Therapeutics? Century Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 742,600 shares, a decrease of 11.9% from the October 31st total of 842,900 shares. Based on an average daily volume of 128,900 shares, the days-to-cover ratio is presently 5.8 days. Approximately 3.1% of the company's stock are short sold. View Century Therapeutics' Short Interest. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) announced its quarterly earnings data on Thursday, November, 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. The business had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.08 million. Century Therapeutics had a negative trailing twelve-month return on equity of 49.28% and a negative net margin of 5,183.16%. When did Century Therapeutics IPO? (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (7.56%), Avidity Partners Management LP (1.84%), Jacobs Levy Equity Management Inc. (0.29%), Charles Schwab Investment Management Inc. (0.25%), New York Life Investment Management LLC (0.17%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.